Phentolamine: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "α 1" to "α<sub>1</sub>") |
ClaireLewis (talk | contribs) |
||
| Line 29: | Line 29: | ||
*Hypersensitivity to phentolamine or components | *Hypersensitivity to phentolamine or components | ||
*[[MI]] | *[[MI]] | ||
* | *CAD | ||
*Angina | *Angina | ||
*Caution if PUD | *Caution if PUD | ||
Revision as of 19:58, 17 September 2019
Administration
- Type: [[α1 Blocker]]; Antidote, Extravasation; Antihypertensive
- Routes of Administration: IV, IM
- Common Trade Names: OraVerse
Adult Dosing
- Pheochromocytomectomy adjunct: 5mg IM/IV q2-4h PRN
- Start: 1-2h preop
- Extravasation (norepinephrine-associated): 5-10mg injected into affected area x1
- Start: within 12h of extravasation
- Hypertensive crisis: 5mg IM/IV q2-4h PRN
Pediatric Dosing
- Pheochromocytomectomy adjunct: 1mg IM/IV q2-4h PRN
- Start: 1-2h preop
Special Populations
- Pregnancy Risk Factor: C
Renal Dosing
- No dosing adjustments
Hepatic Dosing
- No dosing adjustments
Contraindications
- Hypersensitivity to phentolamine or components
- MI
- CAD
- Angina
- Caution if PUD
Adverse Reactions
Serious
- MI
- stroke
- hypotension, severe
- arrhythmias
- PUD
- priapism
Common
- tachycardia
- weakness
- dizziness
- flushing
- orthostatic hypotension
- nasal congestion
- nausea
- vomiting
- diarrhea
Pharmacology
- Half-life: 19 minutes
- Metabolism: Urine
- Excretion: CYP450
Mechanism of Action
References
<Epocrates, UpToDate>
